MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains

Core Viewpoint - MediPharm Labs Corp. reported strong year-over-year revenue growth for Q3 2025, driven by its international medical cannabis strategy, while also reducing costs and increasing cash reserves [2][3]. Financial Performance - Q3 2025 revenue reached $11.4 million, marking a 17% increase from $9.8 million in Q3 2024, attributed to growth in international business [4][8]. - International medical cannabis revenue was $6.4 million, representing 56% of total revenue, with an 83% year-over-year growth [5][8]. - Canadian adult-use and wellness revenue was $1.8 million, reflecting a 4% year-over-year increase and 9% sequential growth from Q2 2025 [5]. Cost Management - Operating expenses decreased to $4.4 million in Q3 2025, down 19% year-over-year and 35% sequentially [9][8]. - Gross profit for the quarter was $2.6 million, with a gross margin of 22%, indicating margin pressure from product mix [7][10]. Cash Position - The company ended Q3 2025 with a cash balance of $10.6 million, an increase of $0.2 million from Q2 2025, supported by disciplined cash management and asset sales [11][12]. Business Strategy - The company expanded its inhaler product line in the domestic market and launched metered dose inhalers in Australia, with plans for future launches in other international markets [6][5]. - Management remains focused on driving revenue growth and streamlining expenses to enhance profitability [3][9].